Long-term combination chemotherapy using eribulin and trastuzumab for three patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

MLA

Hirofumi Nakayama, et al. “Long-Term Combination Chemotherapy Using Eribulin and Trastuzumab for Three Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.” International Cancer Conference Journal, vol. 5, June 2016, pp. 178–82. EBSCOhost, https://doi.org/10.1007/s13691-016-0253-y.

APA

Hirofumi Nakayama, Yoshihiko Segawa, Kazuhiro Araki, Takashi Shigekawa, Ken Shimada, Hirofumi Mukai, & Toshiaki Saeki. (2016). Long-term combination chemotherapy using eribulin and trastuzumab for three patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. International Cancer Conference Journal, 5, 178–182. https://doi.org/10.1007/s13691-016-0253-y

Chicago

Hirofumi Nakayama, Yoshihiko Segawa, Kazuhiro Araki, Takashi Shigekawa, Ken Shimada, Hirofumi Mukai, and Toshiaki Saeki. 2016. “Long-Term Combination Chemotherapy Using Eribulin and Trastuzumab for Three Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.” International Cancer Conference Journal 5 (June): 178–82. doi:10.1007/s13691-016-0253-y.